Apertor is creating novel molecular glues for therapeutic applications in oncology. Our heterobifunctional drugs, called Interceptors, selectively disrupt protein complexes via proximity induction. Apertor is advancing a robust pipeline of projects, leveraging its expertise in synthetic biology and natural products chemistry, and has nominated its first development candidate against solid tumors.